Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01142856 · ClinicalTrials.gov registry record · Phase 1
Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS)
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT01142856: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT01142856 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01142856, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of injecting mesenchymal stem cells through intraspinal delivery for the treatment of ALS.
Interventions
- BIOLOGICAL autologous mesenchymal stem cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2010-06 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01142856
The ClinicalTrials.gov registry entry for NCT01142856 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which autologous mesenchymal stem cells is the first listed.
NCT01142856 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01142856 about?
NCT01142856 is a clinical study titled "Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS)". The purpose of this study is to determine the safety of injecting mesenchymal stem cells through intraspinal delivery for the treatment of ALS.
What is the current status of trial NCT01142856?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2010-06. Estimated completion is 2011-04.
What interventions are being tested in trial NCT01142856?
The interventions under investigation include: autologous mesenchymal stem cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01142856?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.